The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma

Experimental and Molecular Pathology

Volumn 82, Issue 1, 2007, Pages 53-57

  da Costa Andrade, Valéria Cristina ^a   Parise Jr , Orlando ^a,b   Hors, Cora Pereira ^a   de Melo Martins, Poliana Cristina ^a   Silva, Alexandre Pacheco ^a   Garicochea, Bernardo ^a,c  

^a Laboratory of Molecular Genetics   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

FGFR4; Head and neck squamous cell carcinoma; Polymorphism; Prognosis

Indexed keywords

ARGININE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ALLELES; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SURVIVAL ANALYSIS;

EID: 33845922164     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.05.003     Document Type: Article

References (20)

1. 388 allele. Cancer Res. 62 (2002) 840-847
2. Boilly B., Vercoutter-Edouart A.S., Hondermarck H., Nurcombe V., and Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 11 (2000) 295-302
3. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., and Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63 (2003) 1727-1730
4. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.-P., and Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Med. 23 (1999) 18-20
5. Cavallaro U., and Christofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann. N. Y. Acad. Sci. 1014 (2004) 58-66
6. Gervasio O.L., Dutra R.A., Tartaglia S.M., Vasconcellos W.A., Barbosa A.A., and Aguiar M.C. Oral squamous cell carcinoma: a retrospective study of 740 cases in a Brazilian population. Br. Dent. J. 12 (2001) 57-61
7. Gowardhan B., Douglas D.A., Mathers M.E., McKie A.B., McCracken S.R.C., Robson C.N., and Leung H.Y. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br. J. Cancer 92 (2005) 320-327
8. Hasina R., Hulett K., Bicciato S., Di Bello C., Petruzzelli G.J., and Lingen M.W. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 63 (2003) 555-559
9. Jaakkola S., Salmikangas P., Nylund S., Partanen J., Armstrong E., Pyrhonen S., Lehtorvita P., and Nevanlinna H. Amplification of the FGFR4 gene in human breast and gynaecological cancers. Int. J. Cancer 54 (1993) 378-382
10. Jezequiel P., Campion L., Joalland M.-P., Millour M., Dravet F., Classe J.-M., Delacroix V., Deporte R., Fumoleau P., and Ricolleau G. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br. J. Cancer 90 (2004) 189-193
11. Leung H.Y., Gullick W.J., and Lemoine N.R. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int. J. Cancer 59 (1994) 667-675
12. Meric F., Lee W.-P., Sahin A., Zhang H., Kung H.-J., and Hung M.-C. Expression profile of tyrosine kinases in breast cancer. Clin. Cancer Res. 8 (2002) 361-367
13. Morimoto Y., Ozaki T., Ouchida M., Umehara N., Ohata N., Yoshida A., Shimizu K., and Inoue H. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98 (2003) 2245-2250
14. Nagai M.A., Miracca E.C., Yamamoto L., Moura R.P., Simpson A.J., Kowalski L.P., and Brentani R.R. TP53 genetic alterations in head-and-neck carcinomas from Brazil. Int. J. Cancer 76 (1998) 13-18
15. Shimada N., Ishii T., Imada T., Takaba K., Sasaki Y., Maruyama-Takahashi K., Maekawa-Tokuda Y., Kusaka H., Akinaga S., Tanaka A., and Shitara K.A. Neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent anti-tumor activity against androgen-dependent mouse mammary tumors in vivo. Clin. Cancer Res. 11 (2005) 3897-3904
16. Spinola M., Leoni V.P., Tanuma J., Pettinicchio A., Frattini M., Signoroni S., Agresti R., Giovanazzi R., Pilotti S., Bertario L., Ravagnani F., and Dragani T.A. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol. Rep. 14 (2005) 415-419
17. Streit S., Bange J., Fichtner A., Ihrler S., Issing W., and Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int. J. Cancer 111 (2004) 213-217
18. Tabor M.P., Brakenhoff R.H., van Houten V.M., Kummer J.A., Snel M.H., Snijders P.J., Snow G.B., Leemans C.R., and Braakhuis B.J. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 7 (2001) 1523-1532
19. Takahashi A., Sasaki H., Kim S.J., Kakizoe T., Miyao N., Sugimura T., Terada M., and Tsukamoto T. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by different hybridisation technique. Biochem. Biophys. Res. Commun. 257 (1999) 855-859
20. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., Weissman S.M., Hudson T.J., and Flaetcher J.A. FGFR1 is fused with a novel zinc-finger gene, ZNF 198 in the t(8;13) leukemia/lymphoma syndrome. Nat. Genet. 18 (1998) 84-87